MedTrace Logo

Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.

NCT02244164 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2023-02-16

No results posted yet for this study

Summary

Incretinomimetics and inhibitors of dipeptidyl peptidase-4 (DPP-4) are new treatments for diabetes. Previous retrospective studies have shown that these treatments induced an increase in pancreatic mass with potentially a risk for pancreatitis and development of precancerous lesions.

The aim of our study is to provide a better understanding of the pathophysiological mechanisms of increased volume and / or pancreatic exocrine secretion when exposed to certain treatment of type 2 diabetes.

Conditions

Interventions

DRUG

Incretinomimetics

DRUG

DPP-4 inhibitors

Sponsors & Collaborators

  • Erasme University Hospital

    lead OTHER

Principal Investigators

  • Vincent Huberty, MD · Gastroenterology Department Erasme Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2023-02-13
Completion
2023-02-13

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02244164 on ClinicalTrials.gov